faricimab

Contraindicated in:

Hypersensitivity;
Ocular/periocular infections;
Active intraocular inflammation.

Use Cautiously in:

OB: Safety not established in pregnancy;
Lactation: Safety not established in lactation;
Rep: Women of reproductive potential;
Pedi: Safety and effectiveness not established in children.

Adv. Reactions/Side Effects ⬆ ⬇

CV: MI, STROKE

EENT: cataract, ↑intraocular pressure, ↑lacrimation, conjunctival hemorrhage, endophthalmitis, eye irritation, eye pain, intraocular inflammation, retinal detachment, retinal pigment epithelial tear, retinal vascular occlusion, retinal vasculitis, vitreous floater

Misc: hypersensitivity reactions

Interactions ⬆ ⬇

Drug-drug:

None reported

Availability ⬆ ⬇

Solution for intravitreal injection (vials and prefilled syringes): 120 mg/mL

Route/Dosage ⬆ ⬇

Neovascular (wet) Age-Related Macular Degeneration

Intravitreal (Adults ): 6 mg every 4 wk for four doses. Subsequent doses are individualized based on optical coherence tomography and visual acuity evaluations performed 8 and 12 wk later, and are administered as one of the following regimens: Every 8-wk regimen: 6 mg on Weeks 20, 28, 36, and 44; or Every 12-wk regimen: 6 mg on Weeks 24, 36, and 48; or Every 16-wk regimen: 6 mg on Weeks 28 and 44. Some patients may require dosing every 4 wk following the initial 4 doses.

Diabetic Macular Edema

Intravitreal (Adults ): Administer one of the following regimens: Fixed interval regimen: 6 mg every 4 wk for six doses, followed by 6 mg every 8 wk; or Variable interval regimen: 6 mg every 4 wk for at least four doses, followed by 6 mg every 4–16 wk (based on optical coherence tomography and visual acuity evaluations).

Macular Edema Following Retinal Vein Occlusion

Intravitreal (Adults ): 6 mg every 4 wk for 6 mo.

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Inhibits vascular endothelial growth factor-A (VEGF-A), preventing the binding of endogenous VEGF-A, resulting in decreased endothelial proliferation, vascular leakage, and new vessel formation. Also inhibits angiopoietin-2, which promote vascular stability and protects blood vessels from the effects of VEGF-A.

Therapeutic effects:

Decreased progression of visual loss.

Classifications ⬆ ⬇

Therapeutic Classification: ocular agents

Pharmacologic Classification: vascular endothelial growth factor antagonists, monoclonal antibodies, angiopoietin 2 inhibitors

Pharmacokinetics ⬆ ⬇

Absorption: Intravitreal injection results in complete local bioavailability. Very low serum levels are achieved.

Distribution: Unknown.

Metabolism/Excretion: Catabolized in lysosomes to small peptides and amino acids that are excreted renally.

Half-Life: 7.5 days.

Time/Action Profile ⬆ ⬇

ROUTE	ONSET	PEAK	DURATION
Intravitreal	unknown	unknown	unknown

Patient/Family Teaching ⬆ ⬇

Advise patient to notify ophthalmologist immediately if eye becomes red, sensitive to light, painful, or develops a change in vision.
May cause temporary visual disturbances. Caution patient to avoid driving or other activities requiring good eyesight until response to medication is known.
Rep: May cause fetal harm. Advise females of reproductive potential to use highly effective contraception during and 3 mo after last dose. Advise females of reproductive potential to notify health care professional promptly if pregnancy is planned or suspected or if breastfeeding. May impair fertility.

Pronunciation ⬆ ⬇

Code ⬆

NDC Code

50242- Genentech, Inc.
- 50242-096- VABYSMO
  - 50242-096-01- 1 VIAL in 1 CARTON (50242-096-01) / .05 mL in 1 VIAL (50242-096-03)

50242- Genentech, Inc.
- 50242-096- VABYSMO
  - 50242-096-06- 1 SYRINGE in 1 CARTON (50242-096-06) / .05 mL in 1 SYRINGE

50242- Genentech, Inc.
- 50242-096- VABYSMO
  - 50242-096-45- 1 SYRINGE in 1 CARTON (50242-096-45) / .05 mL in 1 SYRINGE

50242- Genentech, Inc.
- 50242-096- VABYSMO
  - 50242-096-86- 1 VIAL in 1 CARTON (50242-096-86) / .05 mL in 1 VIAL (50242-096-77)

section name header

Indications ⬇

Contraind./Precautions ⬆ ⬇